

Index

A

- ACC. *See* Adrenocortical carcinoma
 - ACD. *See* Adrenocortical dysplasia
 - Acute lymphoblastic leukemia (ALL)
 - hypodiploid leukemia
 - diagnosis, 439–441
 - genetics, 441–442
 - models, 445–448
 - TP53* alterations, 442–445
 - overview, 437–438
 - TP53* alterations, 438–439
 - Acute promyelocytic leukemia (APL)
 - PML/RARA fusion, 417–418
 - treatment
 - arsenic trioxide, 418–419
 - normal PML in therapy response, 419–421
 - p53 as effector, 419, 422–423
 - retinoic acid, 418–419
 - ADORA2B*, 104
 - Adrenocortical carcinoma (ACC), 301–303
 - Adrenocortical dysplasia (ACD), *TPP1* mutations, 165
 - Adult stem cell, p53 in differentiation, 5
 - Aging. *See also* Cellular senescence
 - genomic instability, 134
 - telomere shortening. *See* Telomere
 - Aiolos, 441–442
 - AKT, 213–214, 386
 - Aldehyde dehydrogenase, p53 in REDOX
 - management, 223
 - ALL. *See* Acute lymphoblastic leukemia
 - AMG-232, MDM2–p53 interaction therapeutic
 - targeting, 398–400
 - AMP-activated protein kinase (AMPK), p53 studies
 - metabolic sensing, 212–213
 - regulation, 3
 - regulation of metabolism, 219–220
 - AMPK. *See* AMP-activated protein kinase
 - Angiogenesis, gain-of-function p53 mutations,
 - 318–319
 - Anticipation, Li–Fraumeni syndrome, 356–357
 - APC*, 343, 456
 - APE1/Ref-1*, 115
 - APL. *See* Acute promyelocytic leukemia
 - APOBEC*, 288–289, 409
 - Apoptosis
 - gain-of-function p53 mutations and protection in
 - cancer, 319–320
 - p53 studies
 - binding proteins, 146
 - binding site affinity and apoptosis threshold,
 - 146–147
 - cell type and oncogene activity in apoptosis
 - sensitivity, 147
 - functional overview, 141–142
 - induction mechanism, 144
 - mitochondrial function, 145
 - posttranslational modifications in apoptosis
 - regulation, 145–146
 - therapeutic induction, 150–151
 - tumor suppression, 100–101, 147–149
 - ARF, 129, 163, 340
 - ARID1A*, p53 interactions, 76
 - Arsenic trioxide, acute promyelocytic leukemia
 - management, 418–419
 - Asparagine synthetase, mutant p53 target gene, 81, 83
 - ASPP proteins, apoptosis regulation, 146
 - ATM*, 120, 129, 163, 175, 489
 - ATR*, 120, 129, 163, 489
 - ATRX*, 308
 - Aurora kinase, 239
 - Autophagy
 - p53 studies
 - autophagy-related gene activation, 192–193
 - nutrient stress response, 220
 - overview, 3–4
 - suppression by autophagy
 - cancer promotion through p53 repression,
 - 189–192
 - mechanisms, 192
 - overview, 188–189
 - tumor suppression, 104
 - regulation, 187–188
 - Axl
 - mutant p53 target gene, 84
 - p53 mutation effects on expression, 74
- ## B
- BAF, p53 interactions, 76
 - BAP28*, 200
 - Base excision repair (BER), p53 role, 114–116
 - BAX*
 - apoptosis mediation, 101
 - p53 transactivation, 2
 - Bcl-2*, inhibition by p53, 129
 - BER. *See* Base excision repair

Index

- BLM, 120
BNIP3, 225
BOP1, 201
Braf, 191–192
Brazilian *TP53* mutation. *See* p.R337H
BRCA1, 408, 422, 454
BRCA2, 408, 454
BRD7, p53 interactions, 76
Breast cancer
 p53
 isoforms, 38
 status in DNA-damaging therapies, 421–422
 TP53 mutations
 basal-like subtype, 408–409
 molecular subtypes of cancer, 407–408
 overview, 70, 244, 292–293, 407, 456
 prognostic and predictive value, 409–411
 prospects for study, 411–412
BRG1, p53 interactions, 76
- ### C
- Cancer Genome Atlas. *See* TCGA
Cancer stem cell. *See* Stem cell
Carboxy-terminal domain (CTD), structure, 17–18, 22, 71–72
CARM1, p53 transactivation role, 77
Cartilage hair hypoplasia (CHH), 205
CBP. *See* CREB-binding protein
CD3, therapeutic targeting, 484
CDK1, mutant p53 target gene, 82
CDKN1a
 cellular senescence role, 174
 p53 tumor suppression role, 102
CDKN2A, single nucleotide polymorphisms, 476
Cell cycle
 gain-of-function p53 mutations and deregulation, 315
 p53 studies
 arrest mechanism, 142
 cell fate decision between arrest and senescence, 143–144
 cellular senescence induction, 143
 checkpoint functions, 142–143
 cycle regulation and DNA damage repair, 101–103
 functional overview, 141–142
 therapeutic induction, 150–151
 tumor suppression role of arrest, 147–149
 therapeutic targeting of checkpoints, 489–490
Cellular senescence
 cell fate decision between cycle arrest and senescence, 143–144
 chemotherapy response prognosis, 181–182
 fibroblast studies, 173–174
 inflammation, 266–269
 markers, 176
 p53 studies
 chemotherapy induction, 179–181
 induction, 143
 oncogene-induced senescence, 176–178
 pathway, 174–176
 tumor suppression, 103, 178–179
 wild-type p53 tumors, 179
 telomere shortening. *See* Telomere
CHH. *See* Cartilage hair hypoplasia
Chk1, 129
Chk2, 129
CHOR, 199
Chromatin remodeling, p53 transactivation role, 6
Chronic lymphocytic leukemia (CLL), *TP53* mutations, 460
CLL. *See* Chronic lymphocytic leukemia
c-Myc
 mutant p53 target gene, 83
 p53 mutation effects on expression, 73–74
CNV. *See* Copy number variation
Colon cancer, *TP53* mutations, 70, 244
COP1, cancer alterations, 336, 338–339
Copy number variation (CNV), p53 knockout in germline totipotent stem cells, 236–237
CREB-binding protein (CBP), p53 transactivation domain interactions, 60, 62, 76
CRISPR, mutant p53 targeting, 486
CTC1, 167
CTD. *See* Carboxy-terminal domain
CTLA4, therapeutic targeting, 484
CTNNB1, 428
CXCL1, p53 mutation effects on expression, 73–74
- ### D
- DBA. *See* Diamond–Blackfan anemia
DBD. *See* DNA-binding domain
DDB1, 114
DDB2, 114
Diamond–Blackfan anemia (DBA), 204
DKC1, 167
DNA damage repair. *See also* Genome stability
 Caenorhabditis checkpoints, 111–112
 p53 studies
 base excision repair, 114–116
 double-strand break repair, 117–120
 homologous recombination, 119–120
 mismatch repair, 116–117
 nonhomologous end joining, 117–119
 nucleotide excision repair, 113–114
 RecQ helicase interactions, 120–121
 tumor suppression, 101–103
 therapeutic targeting of DNA damage, 489–490
 DNA methylation. *See* Epigenetics
 DNA polymerase β , base excision repair, 116

- DNA-binding domain (DBD)
communication with oligomerization region, 22–24
mutations, 17, 22, 69–70
structure, 17
- DRAM, 192
- Dyskeratosis congenita, telomerase defects, 158, 166–168
- E**
- E2F1, 143, 147
- EBV. *See* Epstein–Barr virus
- EGR1
mutant p53 target gene, 84
p53 mutation effects on expression, 73
- Embryonic stem cell (ESC)
gain-of-function p53 mutation expression effects, 322
p53 in differentiation, 4–5
- EMT. *See* Epithelial-to-mesenchymal transition
- Epidermal growth factor receptor, mutant p53 target gene, 80–81, 83
- Epigenetics
germline totipotent stem cells, 236
p53 in epigenetic regulation of genome, 247–248
- Epithelial-to-mesenchymal transition (EMT)
gain-of-function p53 mutations and cancer, 316–317
p53 studies, 2–3, 8
- Epstein–Barr virus (EBV), oncogenes in p53 pathway inactivation, 341
- ESC. *See* Embryonic stem cell
- Ets-2, mutant p53 interactions, 79–80
- Exposome, *TP53* mutation landscape, 455
- F**
- FAS, apoptosis mediation, 100
- Fatty acid oxidation, p53 regulation of metabolism, 218
- G**
- Gain-of-function p53 mutations
cancer studies
angiogenesis, 318–319
apoptosis protection, 319–320
cancer stem cells, 320–322
cell proliferation, 316
chronic inflammation, 317–318
epithelial-to-mesenchymal transition, 316–317
genomic instability, 319
invasion, 316–317
metabolic shift, 318
metastasis, 317
multidrug resistance, 320
prospects for study, 327–328
therapeutic targeting, 322–323, 485–486
cell cycle deregulation, 315
clinical significance, 78–79
molecular mechanisms, 314–315
mouse models, 78
mut-p53 GOF concept evolution, 312
mutation distribution, 313
overview, 311–312, 406–407
synthetic lethality, 491–492
variability in gain-of-function, 312–314
- Galectin-3, mutant p53 target gene, 83
- GCN5, p53 transactivation domain interactions, 60
- Genome sequencing
TP53 haplotype impact in cancer, 284–286
TP53 mutations
breast cancer, 292–293
clinical classification, 290–292
functional diversity of mutations, 289–290
historical perspective, 279–280
lung cancer, 293–295
next generation sequencing, 285–289
patterns as signatures of mutagenic processes, 285–289
prospects for study, 295–296
somatic mutation spectrum generation, 281–286
status assessment in cancer, 453–454
- Genome stability. *See also* DNA damage repair
aging and genomic instability, 134
cancer
genomic instability, 127–128
p53 inactivation, 134–135
DNA damage and p53 activation, 129–130
gain-of-function p53 mutations and genomic instability, 319
Li–Fraumeni syndrome and genomic instability, 356–357
microRNA and genomic instability, 134
p53-induced pathways for instability prevention, 128–129
p73 role, 132–133
ploidy alterations and p53 regulation, 130–132
prospects for study, 135–136
- GLI2*, 428, 432
- Glucose
p53 regulation of metabolism, 214–220
tolerance and p53 studies, 4
- Glucose transporters (GLUTs), p53 studies
regulation of metabolism, 217
tumor suppression, 103
- GLUTs. *See* Glucose transporters
- GRO1, mutant p53 target gene, 80, 84
- Gutaminase, p53 regulation of metabolism, 217
- H**
- H2AX, 129
- HAUSP, MDM2 regulation in cancer, 340–341

Index

- Helios, 441–442
HIF-1, 223–225
HIPK2, 146
HMGB1, p53 interactions, 24–25, 63
Homologous recombination (HR), p53 role, 119–120
Hotspot mutations, *TP53*, 71
HPV. *See* Human papilloma virus
HR. *See* Homologous recombination
Human papilloma virus (HPV), oncogenes in p53 pathway inactivation, 341
Hypoxia, p53 studies, 223–225
- I**
- Id2, p53 mutation effects on expression, 73
Ikaros, 441–442
Imatinib, 491
Induced pluripotent stem cell (iPSC), gain-of-function p53 mutation expression effects, 321–322
Inflammation
 acute versus chronic, 256
 cancer and chronic inflammation
 association studies, 257–258
 cellular mechanisms, 260
 cellular senescence, 266–269
 p53
 knockout mouse, 262
 nuclear factor- κ B mutual negative regulation, 263–266
 suppression by inflammation, 258–259
 suppression of inflammation, 259–263
 therapeutic targeting, 269–270
 prospects for study, 270–271
 gain-of-function p53 mutations, chronic inflammation, and cancer, 317–318
 overview, 255–256
 pathways, 256
INK4A, 163
iPSC. *See* Induced pluripotent stem cell
Isoforms. *See* p53 isoforms
- K**
- Kaposi's sarcoma, oncogenes in p53 pathway inactivation, 341
KITLG, single nucleotide polymorphisms, 477
KRAS, 343
- L**
- Leukemia inhibitory factor (LIF), p53 in reproductive function, 21
LFS. *See* Li–Fraumeni syndrome
LIF. *See* Leukemia inhibitory factor
Li–Fraumeni syndrome (LFS), 241–242, 249
 age of onset, 354
 anticipation and genomic instability, 356–357
 Brazilian *TP53* mutation. *See* p.R337H
 cancer risk patterns, 355
 clinical definition, 351–352
 genetic modifiers, 356
 genetic testing and counseling, 359–360
 molecular pathogenesis, 352–353
 mouse models, 357–358
 primary tumors and secondary cancers, 354–355
 sex distribution, 353–354
 surveillance, 358–359
 TP53 mutation and tumor associations, 354, 454
 tumor spectrum, 353
LIPIN1, induction by p53, 4
Liposarcoma, p53 pathway inactivation, 343
Liquid biopsy, *TP53* sequencing, 459
Lung cancer
 autophagy promotion through p53 repression, 190–191
 p53 pathway inactivation, 342
 TP53 mutations, 293–295
- M**
- Malic enzyme (ME), p53 regulation of metabolism, 217
MCT. *See* Monocarboxylate transporter
MD. *See* Molecular dynamics
MDM2
 cancer
 amplification, 364–367
 overexpression, 366–374
 overview of alterations, 333–335
 prospects for study, 401–402
 regulators
 ARE, 130, 340
 HAUSP, 340–341
 WIP1, 341
 therapeutic targeting, 150–151, 344–345, 396–402, 484–485
 cell cycle regulation, 143–144
 functional overview, 332–333, 363–364, 395–396
 genomic instability role, 128, 130–131, 133–134
 history of study, 363–364
 Li–Fraumeni syndrome variants, 356
 p53 transactivation domain interactions, 61–62
 ribosomal protein binding
 characterization, 202–203
 overview, 198–199
 single nucleotide polymorphisms and cancer, 474–475
MDM4
 cancer
 alterations, 336–337
 therapeutic targeting, 345, 484–485
 domains
 acidic domain, 382

- p53-associating domain, 380–381
 - RING domain, 381
 - zinc-finger domain, 381–382
- functional overview, 335–336
- history of study, 379–380
- mouse studies, 382–383
- single nucleotide polymorphisms and cancer, 475–476
- MDMX. *See also* MDM4
 - cancer
 - therapeutic targeting, 150–151, 387–388
 - upregulation, 383–386
 - domains
 - acidic domain, 382
 - p53-associating domain, 380–381
 - RING domain, 381
 - zinc-finger domain, 381–382
 - genomic instability role, 133–134
 - history of study, 379–380
 - mouse studies, 382–383
 - p53 transactivation domain interactions, 61
- MDR1
 - gain-of-function p53 mutations and multidrug resistance, 320
 - mutant p53 target gene, 80, 82
 - p53 mutation effects on expression, 73
- ME. *See* Malic enzyme
- Mediator complex
 - mutant p53 interactions, 80
 - p53 transactivation role, 76–77
- Medulloblastoma
 - animal models, 431–432
 - molecular subgroups, 427–428
 - overview, 427
 - p53
 - genomic landscape of mutated medulloblastoma, 430–431
 - somatic and germline aberrations, 428–430
 - therapeutic targeting, 432
- Mesenchymal stem cell (MSC), p53 in differentiation, 5
- Metabolic syndrome, nutrient excess and p53, 220–221
- Metastasis, gain-of-function p53 mutations, 317
- MI-77301, MDM2–p53 interaction therapeutic targeting, 398–399, 401
- MI-888, MDM2–p53 interaction therapeutic targeting, 398–399
- MicroRNA
 - epithelial-to-mesenchymal transition role, 2
 - genomic instability role, 134
- MIRA-1, 487
- Mismatch repair (MMR), p53 role, 116–117
- Mitochondrial outer membrane permeabilization (MOMP), p53 induction, 144–145
- Miz-1, 199
- MMP3, p53 mutation effects on expression, 74
- MMR. *See* Mismatch repair
- Molecular dynamics (MD)
 - p53 domain interaction simulations, 22–24
 - protein–protein interactions, 24–25
- MOMP. *See* Mitochondrial outer membrane permeabilization
- Monocarboxylate transporter (MCT), p53 regulation of metabolism, 218
- MSC. *See* Mesenchymal stem cell
- MSH2, 117
- mTOR
 - autophagy repression, 188
 - cellular senescence and inflammation, 267–268
 - p53 studies
 - metabolic sensing, 212, 214
 - regulation, 3
 - regulation of metabolism, 215, 218–210
- Mut-p53 GOF. *See* Gain-of-function p53 mutations
- MYCN, 428–430
- N**
- NER. *See* Nucleotide excision repair
- Next generation sequencing. *See* Genome sequencing
- NF- κ B. *See* Nuclear factor- κ B
- NF-Y, mutant p53 interactions, 79
- NFI, 441
- NHEJ. *See* Nonhomologous end joining
- NHP2, 167
- NIX, 225
- Nonhomologous end joining (NHEJ), p53 role, 117–119
- NOXA
 - apoptosis mediation, 100–101
 - p53 transactivation, 2, 70
- NSC59984, 487, 492
- Nuclear factor- κ B (NF- κ B)
 - activation and inflammation, 256–257
 - cellular senescence role, 143–144
 - p53
 - mutation effects on expression, 73, 79, 84
 - mutual negative regulation, 263–266
 - suppression by inflammation, 258–259
 - therapeutic targeting, 269–270
- Nucleolar stress, p53 surveillance, 199–202
- Nucleotide excision repair (NER), p53 role, 113–114
- Nutlins, MDM2–p53 interaction therapeutic targeting, 397–399
- NVP-GM097, MDM2–p53 interaction therapeutic targeting, 398, 400
- O**
- OGG1, 115–116
- Oligomerization region
 - communication with DNA-binding domain, 22–24
 - structure, 17, 71

Index

- Oncogene-induced senescence. *See* Cellular senescence
- Ovarian cancer
- p53
 - isoforms, 38
 - pathway inactivation, 342–343
 - TP53 mutations
 - high-grade serous ovarian cancer, 408–409
 - molecular subtypes of cancer, 407–408
 - prognostic and predictive value, 409–411
 - prospects for study, 411–412
- Oxidative stress
- p53 studies, 3, 221–223
 - therapeutic targeting, 490–491
- P**
- p21
- apoptosis inhibition, 2
 - cell cycle arrest, 142
 - cellular senescence role, 175–176
 - p53
 - regulation in induced pluripotent stem cells, 238–239
 - transactivation mechanism, 72, 75, 77
- p53 isoforms
- human isoforms
 - biological activities, 43–45
 - clinical relevance, 37–38
 - regulation of expression and activity, 43
 - types, 33–35
 - prospects for study, 44, 46
 - splice variants, 31–33
 - tools for function studies
 - animal models
 - Drosophila*, 40–41
 - mouse, 41–43
 - zebrafish, 38–40
 - antibodies, 36–37
 - quantitative reverse transcription polymerase chain reaction, 35
 - small interfering RNA, 35–36
 - transactivation functions, 7
 - tumor expression and outcomes, 458–459
- p63
- functional overview, 18–21
 - mutant p53 interactions, 79
 - structure, 18–19
- p73
- functional overview, 18–21
 - genomic stability role, 132–133
 - mutant p53 interactions, 80
 - structure, 18–19
- p300
- mutant p53 interactions, 80
 - p53 transactivation domain interactions, 60, 62, 77
- PAI-1*, 128
- Palb2*, 189
- Pancreatic cancer, autophagy promotion through p53 repression, 191–192
- PARN, 167
- PARP, inhibitors, 484, 488
- Patient-derived tumor xenograft (PDTX), cancer therapy testing, 461
- PC4, p53 transactivation domain interactions, 63
- PCNA
 - mutant p53 target gene, 80, 82
 - p21 interactions, 142
- PD1, therapeutic targeting, 484
- PDGFR, mutant p53 target gene, 84
- PDTX. *See* Patient-derived tumor xenograft
- PFK. *See* Phosphofructokinase
- Phosphofructokinase (PFK), p53 regulation of metabolism, 215, 217
- PIG3, 223
- PIP4K2, 490
- PIRH2, cancer alterations, 336, 338–339
- PML*, 128
- POT1, 160, 163, 165
- p.R337H
 - adrenocortical carcinoma, 301–303
 - clinical considerations, 306–308
 - demography, 304–305
 - functional effects, 305–306
 - genetic diversity of alleles, 303–304
 - genotype–phenotype correlation, 355–356
 - history of study, 301–303
 - prospects for study, 308
- PRIMA-1, 327, 487
- PRIMA-1MET, 327
- PRMT1, p53 transactivation role, 77
- Proline-rich region (PRR), structure, 17, 71
- PRR. *See* Proline-rich region
- PTEN, 246, 456
- PUMA*
 - apoptosis mediation, 100–101
 - p53 transactivation, 2, 70
- Pyruvate dehydrogenase kinase, p53 regulation of metabolism, 217
- R**
- RAD51, 119
- Rap1, 160
- Rb, p53 pathway interactions, 143–144
- RBI*, 456
- Reactive oxygen species. *See* Oxidative stress
- RecQ, p53 interactions, 120–121
- Replication protein A (RPA), p53 transactivation domain interactions, 62–63
- Retinoic acid, acute promyelocytic leukemia management, 418–419

- RETRA, 327
- RG7112, MDM2–p53 interaction therapeutic targeting, 398–400, 402
- RG7388, MDM2–p53 interaction therapeutic targeting, 398, 400–402
- Ribosomal proteins
- extraribosomal functions, 198–199
 - MDM2 binding
 - characterization, 202–203
 - overview, 198–199
 - p53 surveillance of nucleolar stress, 199–202
 - prospects for study, 205–206
 - ribosome biogenesis
 - diseases, 204–205
 - overview, 198
- RITA, 487
- RNA polymerase I, p53 surveillance of nucleolar stress, 199–200
- RNA polymerase II, p53 transactivation role, 6
- RPA, 120
- RPA. *See* Replication protein A
- RPLs. *See* Ribosomal proteins
- RTEL, 167
- S**
- SAH-p53-8, 387
- Schwachman–Diamond syndrome (SDS), 204–205
- SDS. *See* Schwachman–Diamond syndrome
- Senescence. *See* Cellular senescence
- SHH, medulloblastoma defects, 428–432
- Single nucleotide polymorphisms (SNPs)
- CDKN2A*, 476
 - KITLG*, 477
 - MDM2* and cancer, 474–475
 - MDM4* and cancer, 475–476
 - prospects for study in p53 pathway, 477–478
 - TP53*
 - frequency of polymorphisms, 470
 - P72R and cancer, 470–473
 - P72S and cancer, 473–474
- Smad, mutant p53 interactions, 79–80
- SNCAIP*, 428
- SNF5, p53 interactions, 76
- SNPs. *See* Single nucleotide polymorphisms
- Sp1, mutant p53 interactions, 79–80
- SREBP1, p53 regulation of metabolism, 218
- SREBP1c*, repression by p53, 4
- Stathmin, mutant p53 target gene, 84
- Stem cell. *See also specific cells*
- cancer-derived stem cells, 233–235
 - gain-of-function p53 mutations and cancer stem cells, 320–322
 - p53 studies
 - cancer stem cells, 239–240, 459
 - epigenetic regulation of genome, 247–248
 - germline mutation studies, 241–247
 - germline totipotent stem cells, 235–237
 - induced pluripotent stem cells, 238–239
 - maintenance of stem cells, 240–241
 - prospects for study, 248–250
 - self-renewal and tissue regeneration, 237–238
 - pluriipotency, 231–232
 - teratocarcinoma, 235
 - tissue-specific cells, 232–233
 - totipotency, 231–232
- Synthetic lethality, tumor vulnerability targeting, 484, 488, 490–492
- T**
- TAD. *See* Transactivation domain
- TAF9, p53 transactivation domain interactions, 60
- TCAB1, 167
- TCGA, 335–336, 338, 340, 342–344, 368, 370, 372, 405–408, 453
- TCS. *See* Teacher–Collins syndrome
- Teacher–Collins syndrome (TCS), 204
- Telomerase reverse transcriptase (TERT)
- knockout mice, 162
 - mutations, 158
- Telomere
- DNA damage at uncapped telomeres in p53 activation, 162
 - p53
 - dysfunction and translocations, cancer, and aneuploidy, 164–166
 - telomere interplay in vertebrate animal models, 161–162
 - shortening
 - carcinogenesis inhibition, 163–164
 - overview, 157–158
 - senescence role, 160–161
 - structure and function, 159–160
 - telomerase
 - cancer upregulation, 168
 - dyskeratosis congenita defects, 158, 166–168
- TERT. *See* Telomerase reverse transcriptase
- TGF- β . *See* Transforming growth factor- β
- Thioredoxin-interacting protein (TXNIP), 222
- TIGAR
- p53 studies
 - REDOX management, 221
 - regulation of metabolism, 215–217
 - tumor suppression, 103–104
 - therapeutic targeting, 490
- TIM50, p53 mutation effects on expression, 73
- TIN2, 160
- TLR. *See* Toll-like receptor
- Toll-like receptor (TLR), therapeutic targeting, 269–270
- TPP1, 160, 165
- TRAIL, apoptosis mediation, 100

Index

- Transactivation domain (TAD)
 binding partners, 16–17
 discrete domains within amino terminus, 54–55
 functional analysis in vivo, 55, 57–58
 history of study, 51–52
 hydrophobic residues in function, 54
 molecular models for transactivation, 56,
 72, 75–77
 phosphorylative regulation, 63–64
 prospects for study, 64
 protein interactions
 chromatin modifiers, 60
 negative regulators, 61
 table of proteins, 59
 transcription factors, 58, 60
 sequence comparison between species, 53
 structure, 16–17, 61–63, 71–72
Transcriptional superhub, p53 as, 7–9
Transforming growth factor- β (TGF- β), p53 studies
 gain-of-function p53 mutations and cancer, 316
 mutation effects on receptor expression, 74, 83
 signaling role, 5
TRF1, 159–160
TRF2, 159–160, 162–163
TRIM24, cancer alterations, 239, 336, 338–339
Tumor suppression, p53
 apoptosis role, 147–149
 cell cycle arrest role, 147–149
 effector functions
 apoptosis, 100–101
 cell cycle regulation and DNA damage repair,
 101–103
 cellular senescence, 103, 178–179
 metabolism, 103–104
 prospects for study, 104–105
 history of study, 96
 mouse model versus human studies, 105
 oncogenic stress detection and response, 97
 overview, 95–97
 p53 mediation without cell cycle arrest or
 apoptosis, 149
 transcriptional regulation in tumor
 suppression, 97–100
 tumor initiation and progression suppression, 149
TXNIP. *See* Thioredoxin-interacting protein
- U**
USP7, 385
USP22, 386
- V**
VDR. *See* Vitamin D receptor
VEGFR, mutant p53 target gene, 84–85
Vitamin D receptor (VDR)
 p53 mutation effects on expression, 73
 ribosomal protein interactions, 199
- W**
Whole genome sequencing. *See* Genome sequencing
WIP1, MDM2 regulation in cancer, 341
WRN, 120–121
- X**
XPA, 114
XPB, 114
XPC, 114
XPD, 114
XRCC4, 118